Costo-beneficio de cribado de adenocarcinoma gástrico por pepsinógeno sérico en la población mexicana
Uloženo v:
| Název: | Costo-beneficio de cribado de adenocarcinoma gástrico por pepsinógeno sérico en la población mexicana |
|---|---|
| Autoři: | J. Camarillo-Cisneros, J.J. Montelongo-Santiesteban, M. Cisneros-Castolo, A. E. Contreras-Pacheco, A. I. Pérez-Echavarría, David A. Aguirre-Baca, L.B. Enríquez-Sánchez, L.G. Gallegos-Portillo |
| Zdroj: | Revista de Gastroenterología de México (English Edition), Vol 87, Iss 3, Pp 285-291 (2022) Revista de Gastroenterología de México, Vol 87, Iss 3, Pp 285-291 (2022) |
| Informace o vydavateli: | Elsevier BV, 2022. |
| Rok vydání: | 2022 |
| Témata: | Análisis económico, Stomach tumors, Cost-Benefit Analysis, Economic analysis, Neoplasias estomacales, Cribado, RC799-869, Early cancer detection, Diseases of the digestive system. Gastroenterology, Adenocarcinoma, Rentabilidad, Helicobacter Infections, 3. Good health, AVAC, QALY, 03 medical and health sciences, 0302 clinical medicine, Detección precoz del cáncer, Stomach Neoplasms, Pepsinogen A, Screening, Humans, Cost-effectiveness, Mexico |
| Popis: | Helicobacter pylori (H. pylori) is known to be capable of causing chronic inflammation of the gastric mucosa that slowly progresses through the premalignant stages, reaching localized gastric adenocarcinoma (GAC). Its outcome is closely related to the stage at which diagnosis is made. The aim of the present study was to determine cost-benefit by comparing esophagogastroduodenoscopy, serum pepsinogen detection, and no screening at all.Utilizing Markov chains and Monte Carlo simulation, the costs and effects of various detection modalities were simulated to analyze the cost-benefit of each strategy. For our population, we used the published data of patients with gastric cancer, applicable to the Mexican population.The results were reported as incremental cost-effectiveness ratios. The best strategy was serum pepsinogen determination, followed by the strategy of endoscopic examination with continued monitoring every 3 years.The performance of serum pepsinogen serology and directed endoscopic examination (and continued monitoring, if necessary) for GAC screening could be a cost-effective intervention in Mexico, despite the low-to-moderate general prevalence of the disease. |
| Druh dokumentu: | Article |
| Jazyk: | Spanish; Castilian |
| ISSN: | 0375-0906 |
| DOI: | 10.1016/j.rgmx.2021.01.008 |
| DOI: | 10.1016/j.rgmxen.2021.11.002 |
| Přístupová URL adresa: | https://pubmed.ncbi.nlm.nih.gov/34052055 https://pubmed.ncbi.nlm.nih.gov/34794924 https://doaj.org/article/bfd9cf8c505d41cd9e96b90cff10d3dc https://doaj.org/article/c9c64ee87d774a2b9e7dd48c3ca0ef6e https://pubmed.ncbi.nlm.nih.gov/34052055/ https://europepmc.org/article/MED/34052055 https://www.sciencedirect.com/science/article/pii/S0375090621000410 |
| Rights: | CC BY NC ND |
| Přístupové číslo: | edsair.doi.dedup.....430f29ccaffccc0a6da9da22297c2f03 |
| Databáze: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstrakt: | Helicobacter pylori (H. pylori) is known to be capable of causing chronic inflammation of the gastric mucosa that slowly progresses through the premalignant stages, reaching localized gastric adenocarcinoma (GAC). Its outcome is closely related to the stage at which diagnosis is made. The aim of the present study was to determine cost-benefit by comparing esophagogastroduodenoscopy, serum pepsinogen detection, and no screening at all.Utilizing Markov chains and Monte Carlo simulation, the costs and effects of various detection modalities were simulated to analyze the cost-benefit of each strategy. For our population, we used the published data of patients with gastric cancer, applicable to the Mexican population.The results were reported as incremental cost-effectiveness ratios. The best strategy was serum pepsinogen determination, followed by the strategy of endoscopic examination with continued monitoring every 3 years.The performance of serum pepsinogen serology and directed endoscopic examination (and continued monitoring, if necessary) for GAC screening could be a cost-effective intervention in Mexico, despite the low-to-moderate general prevalence of the disease. |
|---|---|
| ISSN: | 03750906 |
| DOI: | 10.1016/j.rgmx.2021.01.008 |